Increasing researches have revealed that the abnormal expression of CDK5 participated in the tumor progression and metastasis across various solid malignancies, including breast cancer, lung cancer, prostate cancer, and liver cancer [22]. This evidence concerns the gene CDK5 and prostate cancer.